The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Diabetology & Metabolic Syndrome

Roland Chen³  Douglas Fleming³  Niklas Berglind²  Robert McNeill¹  Robert Frederich³ 

[1] PMG Research of Salisbury, 401 Mocksville Ave., Salisbury, NC, 28144, USA;AstraZeneca R&D, Kärragatan 5, 431 83, Mölndal, Sweden;Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543, USA

关键词: Type 2 diabetes mellitus;    Titration;    Saxagliptin;    Monotherapy;    DPP-4 inhibitor;   

Others  :  814902
DOI  :  10.1186/1758-5996-4-36

 received in 2012-02-24, accepted in 2012-06-23,  发布年份 2012

【 摘 要 】

Background

The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.

Methods

365 treatment-naïve patients with T2DM (HbA_1c 7.0%–10.0%) were treated with saxagliptin 2.5 mg q.A.M., saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P.M., or placebo. After week 24, patients in all groups were eligible for titration to saxagliptin 10 mg based on HbA_1c ≥7%, and all unrescued placebo patients began blinded metformin 500 mg/day. Rescue with open-label metformin was available for patients with inadequate glycemic control.

Results

At week 24, placebo-subtracted mean HbA_1c reduction from baseline (LOCF) was significantly greater in the saxagliptin treatment groups vs placebo, and remained greater through week 76. Serious adverse events (AEs) and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed hypoglycemia was low across all treatment groups (saxagliptin-treated, 2 [0.7]; control, 1 [1.4]).

Conclusions

In treatment-naïve patients with T2DM, saxagliptin monotherapy demonstrated statistically significant improvement in HbA_1c compared with placebo at 24 weeks and was generally well tolerated for up to 76 weeks.

Trial registration

ClinicalTrials.gov Identifier: NCT00316082

【 授权许可】

   
2012 Frederich et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Khoo J, Rayner CK, Jones KL, Horowitz M: Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag 2009, 5:683-698.
• [2]Onglyza® (saxagliptin): Full Prescribing Information. Princeton, NJ/Wilmington, DE: Bristol-Myers Sqibb/AstraZeneca Pharmaceuticals LP; 2009.
• [3]Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R: Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2006, 25:2401-11.
• [4]DeFronzo R, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, Chen R: Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes 2009, 58:547-P.
• [5]Chacra AR, Tan GH, Ravichandran S, List J, Chen R, CV181-040 Investigators: Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011, 8:150-159.
• [6]Hollander PL, Li J, Frederich R, Allen E, Chen R, CV181-013 Investigators: Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011, 8:125-135.
• [7]Pfützner A, Paz-Pacheco E, Allen E, Frederich B, Chen R, for the CV181039 Investigators: Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011, 13:567-576.
• [8]Dmitrienko A, Offen WW, Westfall PH: Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 2003, 22:2387-2400.
• [9]Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
• [10]Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE: Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139.
• [11]UK Prospective Diabetes Study Group: U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258.
• [12]Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus, CPMP/EWP/1080/00 Rev. 1 [http:/ / www.ema.europa.eu/ docs/ en_GB/ document_library/ Scientific_guideline/ 2010/ 02/ WC500073570.pdf] webcite
• [13]Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
• [14]UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
• [15]Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
• [16]Riddle MC: Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010, 122:844-846.
• [17]Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, The Advance Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
• [18]Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
• [19]Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
• [20]American Diabetes Association: Standards of medical care in diabetes–2010. Diabetes Care 2010, 33:S11-S61.
• [21]Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.